INT186483

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.04
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.92
Pain Relevance 0.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

MYOM2 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 99 98.36 Very High Very High Very High
dexamethasone 385 96.04 Very High Very High Very High
vincristine 4 21.64 Low Low
Central nervous system 2 12.08 Low Low
headache 1 5.04 Very Low Very Low Very Low
aspirin 9 5.00 Very Low Very Low Very Low
peripheral neuropathy 6 5.00 Very Low Very Low Very Low
cytokine 6 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thrombosis Related Under Development 80 98.36 Very High Very High Very High
Influenza Virus Infection 181 96.08 Very High Very High Very High
Amyloidosis 42 94.32 High High
Multiple Myeloma 179 93.38 High High
Infection 31 87.36 High High
Nicotine Addiction 4 80.32 Quite High
Cancer 19 79.96 Quite High
Thrombophilia 7 78.08 Quite High
Pulmonary Disease 93 74.64 Quite High
Disease 89 65.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Among these, personal history of VTD (HR-47.7; P = .006, CI-2.98–766), immobility (HR-11.78; P = .006, CI-2.02–68.8), absence of measurable M-protein (HR-12.5; P = .031, CI-1.25–100), and age at diagnosis (HR-2.99, P = .041, CI-1.05–8.56) were identified as univariable correlates of VTD in amyloidosis patients (Table 4.)
Negative_regulation (absence) of M-protein associated with amyloidosis and cva
1) Confidence 0.04 Published 2005 Journal Int Semin Surg Oncol Section Body Doc Link PMC1232862 Disease Relevance 1.55 Pain Relevance 0.41
Two compounds are available that inhibit function of the M2 protein and prevent viral uncoating following endocytosis.
Negative_regulation (inhibit) of M2 protein
2) Confidence 0.01 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692119 Disease Relevance 1.14 Pain Relevance 0
In a phase II study of 72 patients (median age 63 years) with newly diagnosed MM, induction therapy with clarithromycin 500 mg twice -daily, lenalidomide 25 mg/day on days 1–21 of a 28-day cycle, and dexamethasone 40 mg/day once weekly was associated with an objective response of PR or better in 65 (90.3%) patients (90.3%), including a CR rate of 38.9%.87 Fifty-three patients (73.6%) achieved at least a 90% decrease in M-protein levels.
Negative_regulation (decrease) of M-protein associated with multiple myeloma and dexamethasone
3) Confidence 0.01 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.22 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox